Table IV.
Effects of nitroxoline on KCC853 cell renal tumor orthotopic xenografts in nude mice.
| Drug administration | Anti-cancer activity | Toxicity | |||||
|---|---|---|---|---|---|---|---|
| Drug | Dose, mg/kg | Schedule | Route | Tumor weight, mga | Inhibition rate, % | Body weight loss, %a | Mortalities/total mice, n |
| Control | Vehicle | BID for 21 days | p.o. | 183±73 | 11.8±4.3 | 2/16 | |
| Cisplatin | 5 | QW for 3 weeks | i.v. | 99±35b | 46.0 | 15.0±3.3 | 1/16 |
| Nitroxoline | 60 | BID for 21 days | p.o. | 96±41b | 47.5 | 13.2±5.7 | 2/16 |
| Nitroxoline | 120 | BID for 21 days | p.o. | 89±23b | 51.4 | 9.2±3.7 | 4/16 |
| Nitroxoline | 240 | BID for 21 days | p.o. | 67±28b | 63.7 | 7.7±5.4 | 2/16 |
a
Data are presented as mean ± standard deviation.
b
P<0.001 vs. vehicle control (one-way analysis of variance with Tukey's post-hoc test). BID, twice a day; QW, once a week; p.o., oral; i.v. intravenous.